Emergent BioSolutions Inc. (NYSE: EBS) shares lost ground Tuesday, on the release of a new survey of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65%) of respondents agree the likelihood of a biological attack on U.S. soil is rising, yet almost half (45%) believe the U.S. is unprepared for a biological attack.
Conducted by Penta Group on behalf of Emergent, the survey amplifies findings in the unclassified 2025 Annual Threat Assessment of the U.S. Intelligence Community which highlights continued, serious concerns that adversarial nations possess biological and chemical weapons and that additional countries are continuing their research and development of chemical, biological, and pharmaceutical-based agents
“The risk of bio attacks in the U.S. and around the world is significant, and perhaps even more dangerous than nuclear weapons, given the relative low cost and overall ease to produce, especially today with the enabler of artificial intelligence,” said Andy Weber, Senior Fellow at the Council on Strategic Risk.
“To meet today’s threat we need robust surveillance, stockpiles of PPE and medical countermeasures, and established partnerships to rapidly develop, produce, and deliver vaccines and medicines to address bioengineered or novel threats.”
EBS shares lost eight cents Tuesday to begin trading at $9.62,
